Switzerland
· Delayed Price · Currency is CHF PolyPeptide Group AG Statistics
Total Valuation
PolyPeptide Group AG has a market cap or net worth of CHF 1.09 billion. The enterprise value is 1.15 billion.
| Market Cap | 1.09B |
| Enterprise Value | 1.15B |
Important Dates
The next estimated earnings date is Tuesday, March 11, 2025.
| Earnings Date | Mar 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PolyPeptide Group AG has 32.98 million shares outstanding. The number of shares has increased by 0.00% in one year.
| Shares Outstanding | 32.98M |
| Shares Change (YoY) | +0.00% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 4.41% |
| Owned by Institutions (%) | 19.16% |
| Float | 12.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.47 |
| PB Ratio | 3.15 |
| P/FCF Ratio | 34.21 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 274.56, with an EV/FCF ratio of 36.25.
| EV / Earnings | -42.00 |
| EV / Sales | 3.71 |
| EV / EBITDA | 274.56 |
| EV / EBIT | n/a |
| EV / FCF | 36.25 |
Financial Position
The company has a current ratio of 1.59, with a Debt / Equity ratio of 32.18.
| Current Ratio | 1.59 |
| Quick Ratio | 0.64 |
| Debt / Equity | 32.18 |
| Debt / EBITDA | 26.51 |
| Debt / FCF | 3.50 |
| Interest Coverage | -2.48 |
Financial Efficiency
Return on equity (ROE) is -7.68% and return on invested capital (ROIC) is -3.09%.
| Return on Equity (ROE) | -7.68% |
| Return on Assets (ROA) | -2.34% |
| Return on Capital (ROIC) | -3.09% |
| Revenue Per Employee | 243,970 |
| Profits Per Employee | -21,533 |
| Employee Count | 1,277 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 1.98 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +37.14% in the last 52 weeks. The beta is 1.13, so PolyPeptide Group AG's price volatility has been higher than the market average.
| Beta (5Y) | 1.13 |
| 52-Week Price Change | +37.14% |
| 50-Day Moving Average | 30.80 |
| 200-Day Moving Average | 24.97 |
| Relative Strength Index (RSI) | 50.38 |
| Average Volume (20 Days) | 40,955 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PolyPeptide Group AG had revenue of CHF 311.55 million and -27.50 million in losses. Loss per share was -0.84.
| Revenue | 311.55M |
| Gross Profit | 16.56M |
| Operating Income | -22.56M |
| Pretax Income | -30.16M |
| Net Income | -27.50M |
| EBITDA | 430,381 |
| EBIT | -22.56M |
| Loss Per Share | -0.84 |
Balance Sheet
The company has 46.67 million in cash and 111.51 million in debt, giving a net cash position of -64.83 million or -1.97 per share.
| Cash & Cash Equivalents | 46.67M |
| Total Debt | 111.51M |
| Net Cash | -64.83M |
| Net Cash Per Share | -1.97 |
| Equity (Book Value) | 346.54M |
| Book Value Per Share | 10.51 |
| Working Capital | 104.98M |
Cash Flow
In the last 12 months, operating cash flow was 82.11 million and capital expenditures -50.24 million, giving a free cash flow of 31.86 million.
| Operating Cash Flow | 82.11M |
| Capital Expenditures | -50.24M |
| Free Cash Flow | 31.86M |
| FCF Per Share | 0.97 |
Margins
Gross margin is 5.32%, with operating and profit margins of -7.24% and -8.83%.
| Gross Margin | 5.32% |
| Operating Margin | -7.24% |
| Pretax Margin | -9.68% |
| Profit Margin | -8.83% |
| EBITDA Margin | 0.14% |
| EBIT Margin | -7.24% |
| FCF Margin | 10.23% |
Dividends & Yields
PolyPeptide Group AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.00% |
| Shareholder Yield | -0.00% |
| Earnings Yield | -2.54% |
| FCF Yield | 2.92% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |